v3.25.1
Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Research and development expenses:    
Expenses incurred $ 64 $ 375
Less- government participation (41) (180)
Research and development expenses, net 23 195
Marketing expenses 2 168
General and administrative expenses 228 295
Total operating loss 253 658
Financial (income) expense, net 520 (1)
Loss for the period $ 773 $ 657
Basic loss per common stock $ (0.01) $ (0.01)
Dilutive loss per common stock $ (0.01) $ (0.01)

Source